U.S. Stock Futures Wobble as Earnings Season Begins - The Wall Street Journal
U.S. stock futures wavered Tuesday at the start of earnings season with several large U.S. banks reporting this morning.
Futures tied to the S&P 500 edged down 0.1%, suggesting stocks could come under pressure after the opening bell. A rally in megacap tech stocks led the broad market index on Monday to its second-highest close in history. Futures linked to the Nasdaq-100 ticked up 0.9%
Johnson & Johnson has paused a coronavrius-vaccine trial, triggering concern that this and other vaccines under development may be delayed.
Photo: Cheryl Gerber/Associated PressUncertainty about a second wave of coronavirus infections and the extent to which governments may have to renew restrictions to control the spread are weighing on investors’ minds as the third-quarter earnings season kicks off on Tuesday.
“Earnings season will create a lot of volatility, especially ahead of the election,” said Ludovic Subran, chief economist at Allianz. “The market focus will remain on financial and tech earnings: this will be a main driver.”
BlackRock shares added 2.8% premarket after it reported third-quarter profit that was above expectations and revenue that rose above forecasts. JPMorgan Chase shares gained 1.3% after it posted earnings per share above expectations, but also said it would extend the suspension on stock repurchases at least through the end of the fourth quarter. Shares of Citigroup rose 1.1% after the bank reported earnings per share well above estimates, although it was still a 32% decline from the same period last year.
Johnson & Johnson shares slid 1.3% ahead of the New York opening bell after it halted its coronavirus vaccine trials due to a participant becoming unexpectedly sick, prompting fresh speculation about when immunization shots may become widely available. The company also revised up its full-year expectations for adjusted operational sales in its earnings report.
J&J’s vaccine is one of the most advanced Covid-19 shots in development, and is among just a handful that had entered the last stage of testing in the U.S. This is the second time such a trial has been put on hold over a safety concern: AstraZeneca has since resumed its testing efforts in the U.K., but its clinical trials in the U.S. remain suspended.
“It’s a reminder that while we have this race to get a vaccine, it could actually take longer,” said Paul Jackson, global head of asset-allocation research at Invesco. People are also being too optimistic over how quickly a vaccine can halt the pandemic, he cautioned. “If we get one through the trials and authorized, that would be a great step, but then it will still take quite some time to get it widely distributed.”
In bond markets, the yield on benchmark 10-year Treasury notes edged down to 0.760%, from 0.775% on Friday.
Traders are also awaiting the latest inflation data, due out at 8:30 a.m. ET. Consumer prices are expected to have risen in September for a fourth consecutive month. But inflation pressure is still likely to be muted, keeping the door open for the Federal Reserve to continue with its easy-money policy.
In trading ahead of the opening bell, Walt Disney rose 4.2% after it announced a major reorganization of its business to focus more on streaming. Apple’s shares added 1.4% ahead of a company presentation scheduled for Tuesday where it is expected to unveil the next iPhone.
Overseas, the pan-continental Stoxx Europe 600 fell 0.1%.
In Asia, most major benchmarks were mixed by the close of trading. The Shanghai Composite Index was flat after trade data showed that Chinese exports rose nearly 10% in September, reflecting a continuing recovery. Markets in Hong Kong were closed due to Tropical Storm Nangka being slated to hit the city.
The International Monetary Fund is also set to put out an updated outlook for global economic growth at 8:30 a.m., as finance ministers and central bankers gather virtually for the IMF and World Bank’s annual meetings.
Write to Anna Hirtenstein at anna.hirtenstein@wsj.com
Copyright ©2020 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
https://ift.tt/2GKXH3v
Comments
Post a Comment